NewsRx

Search our medical news database

Merck

Officials at Merck discuss recent developments

Published in Medical Verdicts and Law Weekly, December 14th, 2006

Officials at Merck discuss recent developments.

This trend article is an immediate alert from NewsRx to identify the most recent news developments at Merck.

Report 1: Merck & Co., Inc., Whitehouse Station, New Jersey, U.S., and H. Lundbeck A/S, Denmark, announced that submission of a new drug application (NDA) for gaboxadol with the U.S. Food and Drug Administration will no longer occur in the first quarter of 2007. The companies plan to submit the NDA in mid-2007.

The delay in the NDA submission for gaboxadol, an investigational drug in phase 3 development for the treatment of insomnia, results from slower than anticipated...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook